Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the drug telbivudine (LdT) for treatment of hepatitis B virus (HBV)
in HIV infected patients. Patients will take telbivudine alone for 24 weeks, add anti-HIV
drugs for 24 weeks, then stop taking telbivudine while continuing their anti-HIV drug
regimen. To enroll in this study, patients must not be taking any anti-HIV drugs and cannot
have taken more than 31 days of treatment with lamivudine (3TC), protease inhibitors (PIs),
or nonnucleoside reverse transcriptase inhibitors (NNRTIs).
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)